Results 231 to 240 of about 19,791 (256)
Some of the next articles are maybe not open access.

Psoralen Phototherapeutic Agents

JAMA: The Journal of the American Medical Association, 1967
Photosensitizers have been used in medicine for several thousand years. In the past, the effect being sought was repigmentation of light areas in the skin. Most of the orally administered or locally applied preparations were obtained from plants that contain psoralen (furocoumarin).
openaire   +3 more sources

Kinetic study on pyrolysis of psoralen

China Journal of Chinese Materia Medica, 2012
In this study, products of psoralen pyrolysis were detected using a solid pyrolysis apparatus and synchrotron radiation vacuum ultraviolet photoionization mass spectrum (SVUV-PIMS). The pyrolytic kinetics of psoralen was also studied by calculating its initial pyrolytic route in quantum chemistry.
Liao Kun   +6 more
openaire   +3 more sources

Eye protection in psoralen photochemotherapy

British Journal of Dermatology, 1981
The optical performance of some commercially-available tined lenses is discussed. There is a wide variation in the UV absorbing power of sunglasses although adequate protection against solar UV-A can be achieved with some, but not all, polarizing material.
B. L. Diffey, J.B. Davey, J. A. Miller
openaire   +3 more sources

The reaction of the psoralens with deoxyribonucleic acid

Quarterly Reviews of Biophysics, 1984
Psoralen photochemistry is specific for nucleic acids and is better understood at the molecular level than are all other methods of chemical modification of nucleic acids. These compounds are used both forin vivostructure analysis and for photochemotherapy since they easily penetrate both cells and virus particles.
Kenneth Straub   +4 more
openaire   +3 more sources

Psoralen therapy in vitiligo

Clinics in Dermatology, 1989
Abstract Vitiligo is an idiopathic, acquired, circumscribed hypomelanosis, which is often associated with a positive family history. It is one of the most common leukodermas affecting approximately 1–4% of the world's population. 1 Vitiligo is characterized by discrete pale white macules, few or many in number that tend to enlarge centrifugally over
openaire   +3 more sources

Psoralen Photochemotherapy (PUVA) and Pregnancy

Archives of Dermatology, 1993
Psoralen photochemotherapy (PUVA) may carry a risk of mutagenesis and teratogenesis. Using a medical birth registry and other health registries, infants born to women who had been treated with PUVA were identified. Exposure information was obtained from treating hospitals and from the license-granting agency.
Bernt Lindelöf   +3 more
openaire   +3 more sources

TREATMENT OF VITILIGO WITH PSORALEN DERIVATIVES

Archives of Dermatology, 1955
COSMETIC disfiguration and psychologic sequelae constitute a serious problem for the patient with vitiligo. Reported successful treatment of this condition with the psoralen derivatives has stimulated considerable interest among physicians, but the frequent occurrence of undesirable side effects from local and oral application has discouraged their use.
James W. Burks, William M. George
openaire   +2 more sources

Psoralen Photobiology: Recent Advances

Photochemistry and Photobiology, 1996
Clinical efficacy may arise from psoralen-induced photodamage by the induction of a panoply of biomolecules. In cellular studies with UV or photoactivatable agents, the activation of NF-kappa B, probably the most widely studied transcription factor, occurs after its release from an inhibiting factor, I kappa B.
openaire   +3 more sources

The Treatment of Vitiligo with Psoralen Derivatives

Archives of Dermatology, 1958
During the past three years 123 patients with vitiligo have been treated with psoralen derivatives in the Dermatology Clinic, Christian Medical College Hospital, Vellore, South India. Because vitiligo is particularly disfiguring in an Indian patient, it often gives rise to severe psychological strain as well as to social stigma.
openaire   +2 more sources

Synthesis of Psoralens [PDF]

open access: possiblePlanta Medica, 2009
A. S. Rao, I. A. Khan, T. J. Smillie
openaire   +1 more source

Home - About - Disclaimer - Privacy